IMMUNOHISTOCHEMICAL EXPRESSION OF PDL1 IN SEROUS CARCINOMA OVARY
Not Applicable
- Conditions
- Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
- Registration Number
- CTRI/2021/07/034814
- Lead Sponsor
- Dr Anubhuti Chaturvedi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Cases diagnosed as Serous Ovarian Cancer on Histopathology
Exclusion Criteria
•Other Histological types of Epithelial Ovarian Carcinomas- Endometrioid, Clear cell, and Mucinous type
•Other types of Ovarian Carcinomas- Germ Cell, Sex cord-Stromal
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Outcome: <br/ ><br>To assess the immunohistochemical expression of PDL1 marker in Serous Carcinoma of the Ovary. <br/ ><br>Timepoint: 1 year
- Secondary Outcome Measures
Name Time Method Secondary Outcome: <br/ ><br>To study the association of PDL1 expression with Tumor Infiltrating Lymphocytes (TILs) in Serous Carcinoma of the Ovary. <br/ ><br>Timepoint: 1 year